Introduction
============

Gastric cancer is rampant in many countries around the world ([@b1-ol-0-0-9190]). According to Globocan 2012, gastric cancers rank as the 4th most common malignancy, accounting for more than 6.8% of adult malignancies; and the third leading cause of cancer death worldwide, accounting for more than 8.8% of adult malignancie; especially in China, gastric cancer causing approximately 325,000 deaths per year ([@b2-ol-0-0-9190]). It\'s well known that prognosis of gastric cancer remains poor due to the lack of effective therapies in patients with advanced cancer ([@b2-ol-0-0-9190],[@b3-ol-0-0-9190]).

Immunotherapy has become one of the most promising treatments in gastric cancer, especially immunotherapy targeting the immune checkpoints programmed cell death protein-1 (PD-1) and programmed death-ligand-1 (PD-L1) ([@b4-ol-0-0-9190]). PD-1, a cluster of differentiation (CD)28 family member, is an immunosuppressive receptor expressed on T cells, B cells, monocytes, natural killer cells (NKs) and many tumor-infiltrating lymphocytes (TILs) ([@b5-ol-0-0-9190],[@b6-ol-0-0-9190]). Previous studies have shown that high-PD-1/CD4 ratio was associated with poor prognosis in NSCLC patients ([@b7-ol-0-0-9190]); high proportion of PD-1^+^CD4^+^ T cells in the peripheral blood cells of PDAC patients was correlated to chemotherapy resistance ([@b8-ol-0-0-9190]); high surface expression of PD-1^+^CD8^+^ T cells confered worse relapse-free and overall survival (OS) rates in patients with colorectal cancer ([@b9-ol-0-0-9190]); an overall low PD-1 and a concurrent high CD3^+^ T cells expression was found in high-risk prostate cancer tissue ([@b10-ol-0-0-9190]). All these results indicated that the surface expression of PD-1 on T-cells was tightly associated with the prognosis of cancer patients.

Recent studies have confirmed the expression of PD-1 and its relationship with prognosis in gastric cancer patients ([@b11-ol-0-0-9190]). In this study, we clarify the significance of PD-1 expression on peripheral blood T-cell subsets, then explore the relationships between PD-1 and the clinicopathological features and prognosis of patients with metastatic gastric cancer.

Patients and methods
====================

### Patients

A total of 100 outpatients with metastatic gastric cancer met the inclusion criteria from the Zhengzhou University Affiliated Cancer Hospital (Zhengzhou, China) were enrolled in the study between May 2015 and May 2016. The inclusion criteria were listed as follows: i) The diagnosis of metastatic gastric cancer was confirmed by endoscopic biopsy and imageological examination; ii) the disease was classified as pathologic M1 with any T and N stage based on the standard of the WHO Classification of Tumors of the Digestive System, 2010 edition ([@b12-ol-0-0-9190],[@b13-ol-0-0-9190]); iii) 2 ml peripheral blood was drawn before the first line therapy; iv) patients had completed 4 courses of first line chemotherapy as documented in the medical record; and v) complete follow-up data was available. This study was approved by the ethics committee at the Zhengzhou University Affiliated Cancer Hospital, and informed consent form was signed by every patient. The clinical characteristics of these patients were detailed in [Table I](#tI-ol-0-0-9190){ref-type="table"}.

### Treatment and response

Oxaliplatin (130 mg/m^2^ d1, every 3 weeks) combined with Capecitabine (1,000 mg bid d1-14, every 3 weeks) was undergone as the first line chemothrapy. Therapeutic efficacy was evaluated every 2 cylcles of chemotherapy. The follow-up was performed until July 30, 2017. progression-free survival (PFS) was calculated from the date of first treatment to the date of progression or death/censoring. OS was calculated from the date of first treatment to the date of death or censoring. The therapy regimen was replaced when the patient emerged progressive disease.

### Preparation of peripheral blood mononuclear cells (PBMCs)

Approximately 40 ml of peripheral blood was drawn from the patients on the day before surgery and on the day before the first line therapy. A Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient was used to centrifuge blood samples.

### Flow cytometric analysis

PBMC (1×10^5^) were suspended in PBS supplemented with 20% human AB serum and incubated on ice with appropriate dilution of antibodies for 30 min. All antibodies used in this study including anti-CD3-PE-Cy7, anti-CD4-PerCP-Cy5-5, anti-CD8-APC, anti-CD279 (PD-1)-FITC, were purchased from BioLegend (San Diego, CA, USA). APC mouse IgG1(j) (clone MOPC-21), PE-Cy7 mouse IgG2b(j) (clone MPC-11), PerCP-Cy5-5 mouse IgG1(j) (clone MOPC-21) and FITC mouse IgG2b(j) (clone 27--35; all BioLegend), were used as isotype controls. Additionally, FMO plus isotype controls were used to help us gate the negative and positive populations of CD3, CD4, CD8 and PD-1 ([@b14-ol-0-0-9190]). Briefly, when we run flowcytometry, we stained all antibodies to observe the expression of CD3, CD4, CD8 and PD-1, however, we also stained CD3, CD4, CD8 and FITC mouse IgG2b as FMO plus isotype control of PD-1 expression. The similar method was used to distinguish the negative and positive populations of CD3, CD4, and CD8. The staining cells were analyzed on BD FACS Canto II with FACS Diva software (BD Biosciences, Franklin Lakes, NJ, USA).

### Statistical analysis

All statistical analyses were performed using SPSS 24.0 (IBM Corp., Armonk, NY USA). Difference between two groups was analyzed by student t-test, and difference between multiple groups was analyzed by one way ananlysis of variance with Tukey\'s post hoc test. Kaplan-Meier curve with the log rank test was used in survival analysis. Prognostic factors were examined by univariate and multivariate analysis on the basis of Cox proportional hazards model were used for. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression of PD-1 on peripheral blood lymphocytes

We detected the surface expression of PD-1 on lymphocytes from the PBMCs of patients with metastatic gastric cancer, and focused on the expression of PD-1 on CD3^+^, CD3^+^CD4^+^ and CD3^+^CD8^+^ T-cell subsets. The representative staining patterns of PD-1 on these subsets were shown in [Fig. 1](#f1-ol-0-0-9190){ref-type="fig"}. For further analysis, we defined that lymphocytes with PD-1^+^/CD3^+^ \>15%, PD-1^+^/CD3^+^CD4^+^ \>10%, or PD-1^+^/CD3^+^CD8^+^ \>5% showed high surface PD-1 expression on T-cell subsets by using isotype-matched control, on the contrary PD-1 expression level is low. The percent of CD3^+^, CD3^+^CD4^+^ and CD3^+^CD8^+^ T-cells with high surface PD-1 expression were 20.4, 13.0 and 9.4%, respectively.

### Relationship between PD-1 expression on peripheral blood T-cell subsets and clinicopathological factors in metastatic gastric cancer

The correlation between PD-1 expression on peripheral blood T-cell subsets and clinicopathological factors of patients with metastatic gastric cancer was analyzed. However, no correlation was found between PD-1 expression on peripheral blood T-cell subsets and clinicopathological factors of patients with metastatic gastric cancer (all P\>0.05) ([Table I](#tI-ol-0-0-9190){ref-type="table"}).

### Relationship between PD-1 expression on peripheral blood T-cell subsets and OS in metastatic gastric cancer

The correlation of PD-1 expression on peripheral blood T-cell subsets with the prognosis of patients with metastatic gastric cancer was analyzed. The OS and PFS rate of the 100 patients with metastatic gastric cancer were 12.2 and 3.9 months, respectively ([Fig. 2](#f2-ol-0-0-9190){ref-type="fig"}). The 1-year and 2-year OS rates were 53.0 and 2%, respectively.

Kaplan-Meier survival analysis revealed that patients with high PD-1^+^/CD3^+^, PD-1^+^/CD3^+^CD4^+^, and PD-1^+^/CD3^+^CD8^+^ level showed worse prognosis compared with patients with low PD-1^+^/CD3^+^, PD-1^+^/CD3^+^CD4^+^, and PD-1^+^/CD3^+^CD8^+^ level (all P\<0.05) ([Fig. 3](#f3-ol-0-0-9190){ref-type="fig"}). Univariate analysis was performed to estimate the clinical significances of various parameters that may affect survival of patients with metastatic gastric cancer. As shown in [Table II](#tII-ol-0-0-9190){ref-type="table"}, Karnofsky performance score (KPS) scores \[hazard ratio (HR); 2.059; P=0.043\], tumor differentiation (HR, 2.167; P=0.031), number of metastatic organs (HR, 3.041; P=0.032), liver metastasis (HR, 3.234; P=0.047), peritoneal metastasis (HR, 2.567; P=0.038), high PD-1^+^/CD3^+^ level (HR, 2.066; P=0.005), high PD-1^+^/CD3^+^CD4^+^ level (HR, 1.857; P=0.028), and high PD-1^+^/CD3^+^CD8^+^ level (HR, 1.796; P=0.023) were all predictive factors for prognosis of patients with metastatic gastric cancer. Then multivariate analysis based on Cox\'s proportional hazards model was performed to determine the independent prognostic factors for patients with metastatic gastric cancer in our cohort. The results indicated that high PD-1^+^/CD3^+^ (HR, 2.145; P=0.015), high PD-1^+^/CD3^+^CD4^+^ (HR, 1.866; P=0.034), and high PD-1^+^/CD3^+^CD8^+^ (HR, 1.817; P=0.033) level were independent risk factors for predicting the survival time of metastatic gastric cancer ([Table III](#tIII-ol-0-0-9190){ref-type="table"}).

Furthermore, we compared the prognostic value of PD-1 expression on peripheral blood T-cell subsets for OS with that of other independent prognostic factors using receiver operating characteristics (ROC) curves, which showed that the PD-1^+^/CD3^+^ expression was not different from PD-1^+^/CD3^+^CD4^+^ with regards to OS, and the PD-1^+^/CD3^+^CD4^+^ expression was not different from PD-1^+^/CD3^+^CD8^+^ with regards to OS ([Fig. 4](#f4-ol-0-0-9190){ref-type="fig"}). Interestingly, when we compared PD-1^+^/CD3^+^ with PD-1^+^/CD3^+^CD8^+^, the PD-1^+^/CD3^+^CD8^+^ had a better prognostic value than PD-1^+^/CD3^+^ ([Fig. 4](#f4-ol-0-0-9190){ref-type="fig"}).

Discussion
==========

Recently, immunotherapy has become a promising treatment for many types of cancers, including gastric cancer, which has given rise to a growing interest in cancer immunotherapy ([@b15-ol-0-0-9190]). Many clinical trials have demonstrated that anti-PD-1 therapy was a successful treatment for malignancies, including NSCLC, metastatic melanoma, renal cell carcinoma, Hodgkin\'s lymphoma, and metastatic gastric cancer ([@b16-ol-0-0-9190]--[@b18-ol-0-0-9190]). It has been indicated that PD-1 and PD-L1 expression were independent prognosis factors in gastric cancer by immunohistochemistry (IHC) analysis ([@b19-ol-0-0-9190]--[@b22-ol-0-0-9190]). Since it is difficult to get fresh specimens from patients to determine the expression of PD-1 or PD-L1 expression by IHC, no uniform standard was defined for PD-L1 positivity up to now. Eto *et al* defined PD-L1 positivity by staining of the tumor-cell in four grade: 6--25, 26--50 or 51--75 and 76--100% of cells ([@b12-ol-0-0-9190],[@b23-ol-0-0-9190]--[@b29-ol-0-0-9190]); Ti Wen and co-worker defined staining pattern of PD-L1 as positive if \<5 or ≥5% in tumor cells ([@b13-ol-0-0-9190]); whereas Wenfeng Fang assessed the expression of PD-L1 by semi-quantitative H-score and defined cases with greater than 10% PD-L1 expression on tumor cells were considered positive ([@b26-ol-0-0-9190]). Therefore, consistency detection of PD-1 and PD-L1 expression by IHC is limited due to the difference of antibody qualities from different manufacturers, the interpretative subjectivity, and the different standard on positivity thresholds.

For the development of new treatment modalities, the co-development of novel convenient detection methods of biomarkers is important. Here, we detected PD-1 expression in PBMC from patients with metastatic gastric cancer using flow cytometry analysis, which was an antibody-independent assay for PD-1 protein detection of circulation. To analysis the role of the expression level of PD-1 on peripheral blood T-cell subsets in clinicopathological factors and prognosis of patients with metastatic gastric cancer, we defined that lymphocytes with PD-1^+^/CD3^+^ \>15%, PD-1^+^/CD3^+^CD4^+^ \>10%, or PD-1^+^/CD3^+^CD8^+^ \>5% showed high PD-1 expression level on T-cell subsets, on the contrary PD-1 expression level is low. However, our data indicated that there was no significant difference on the expression level of PD-1 on peripheral blood T-cell subsets between patients with high PD-1^+^/CD3^+^, PD-1^+^/CD3^+^CD4^+^, PD-1^+^/CD3^+^CD8^+^ expression and patients with low PD-1^+^/CD3^+^, PD-1^+^/CD3^+^CD4^+^, PD-1^+^/CD3^+^CD8^+^ expression.

In addition, the expression of PD-1 showed no correlation with clinicopathological factors of patients with metastatic gastric cancer. Then, we analyzed the correlation between PD-1^+^/CD3^+^, PD-1^+^/CD3^+^CD4^+^, PD-1^+^/CD3^+^CD8^+^ expression and PFS, the data demonstrated that patients with high PD-1^+^/CD3^+^, PD-1^+^/CD3^+^CD4^+^, PD-1^+^/CD3^+^CD8^+^ level showed worse OS. Further multivariate analysis using Cox\'s proportional hazards model indicated that high PD-1^+^/CD3^+^, PD-1^+^/CD3^+^CD4^+^, and PD-1^+^/CD3^+^CD8^+^ were independent risk factors for predicting the survival of metastatic gastric cancer.

Furthermore, ROC analysis suggested that PD-1^+^/CD3^+^CD4^+^ expression has a similar survival predictive ability as PD-1^+^/CD3 and PD-1^+^/CD3^+^CD8^+^, while PD-1^+^/CD3^+^CD8^+^ higher predictive ability than PD-1^+^/CD3, implying that identification of PD-1^+^/CD3^+^CD8^+^ in patients might be a more straightforward procedure.

Cumulative studies revealed that PD-L1 was widely expressed in human malignancies and was a component of the immunosuppressive microenvironment ([@b24-ol-0-0-9190]). A problems that cannot be neglected is that the heterogeneity of fresh specimens and peripheral blood. It was not clear the status of PD-1 expression on peripheral blood accurately reflect the status of PD-1 expression in tumor microenvironment. However, tumor-derived DNA and RNA can be released and circulated in the peripheral circulation of cancer patients, which operationally allowing for non-invasive gene expression profiling by body fluid analysis. Indeed, there is a wealth of information indicating a correlation between tumor-associated changes in genomic, epigenetic, or transcriptional patterns and alterations in the levels of cell-free circulating nucleic acids (cfCNAs) ([@b30-ol-0-0-9190],[@b31-ol-0-0-9190]). Thus, detected PD-L1 in peripheral blood may after all be accepted as a kind of practical methods for prostraction of disease progression. In the other hands, although we did not determined the expression of PD-L1 and PD-L2, two ligands for PD-1, on peripheral blood T-cell subsets in the present study, it has been already demonstrated that PD-L1 expression in gastric cancer cells was significantly correlated with worse prognosis in gastric cancer patients ([@b32-ol-0-0-9190]). As to PD-L2, which deliver co-inhibitory signal by binding to PD-1, it is very interesting to determine PD-L2 expression on peripheral blood T-cell subsets to see its role on immune evasion in gastric cancer patients.

In conclusion, in our cohort, PD-1 expression on peripheral blood T-cell subsets is an independent prognostic factor in metastatic gastric cancer, suggest that PD-1 expression in peripheral blood T-cell subsets may potential be a novel prognostic marker for gastric cancer patients at advanced stage.
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![Representative staining patterns of PD-1 on peripheral blood T-cell subsets from PBMC of patients with metastatic gastric cancer. (A) The baseline for the PD-1 staining was determined using an isotype-matched control. The expression of (B) PD-1^+^/CD3^+^, (C) PD-1^+^/CD3^+^CD4^+^ and (D) PD-1^+^/CD3^+^CD8^+^ from PBMC of patients with metastatic gastric cancer. CD, cluster of differentiation; PD-1, programmed cell death protein 1; BMC, peripheral blood mononuclear cells.](ol-16-04-4448-g00){#f1-ol-0-0-9190}

![Survival of patients with metastatic gastric cancer following first line therapy. Kaplan-Meier survival curves showed the (A) overall survival and (B) progression-free survival of metastatic gastric cancer patients following the first line therapy.](ol-16-04-4448-g01){#f2-ol-0-0-9190}

![OS of metastatic gastric cancer patients following first line therapy. (A) Kaplan-Meier survival curves with log-rank method showed the OS of patients with metastatic gastric cancer following first line therapy (high PD-1^+^/CD3^+^ vs. low PD-1^+^/CD3^+^). (B) Kaplan-Meier survival curves with log-rank method showed the OS of patients with metastatic gastric cancer following first line therapy (high PD-1^+^/CD3^+^CD4^+^ vs. low PD-1^+^/CD3^+^CD4^+^). (C) Kaplan-Meier survival curves with the log-rank method revealed the OS of patients with metastatic gastric cancer from first line therapy (high PD-1^+^/CD3^+^CD8^+^ vs. low PD-1^+^/CD3^+^CD8^+^). OS, overall survival; PD-1, programmed cell death protein 1; CD, cluster of differentiation; HR, hazard ratio.](ol-16-04-4448-g02){#f3-ol-0-0-9190}

![Difference of prognostic value among PD-1+/CD3+, PD-1+/CD3+CD4+, and PD-1+/CD3+CD8+. Receiver operating characteristics curves for overall survival. P-values show the area under the receiver operating characteristics among the PD-1+/CD3+, PD-1+/CD3+CD4+, and PD-1+/CD3+CD8+. PD-1, programmed cell death protein 1; CD, cluster of differentiation; AUC, area under the curve; SE, standard error; Cl, confidence interval.](ol-16-04-4448-g03){#f4-ol-0-0-9190}

###### 

Association between PD-1 expression on peripheral blood T-cell subsets and clinicopathological factors in patients with metastatic gastric cancer.

                                      PD-1^+^/CD3^+^        PD-1^+^/ CD3^+^CD4^+^        PD-1^+^/ CD3^+^CD8^+^                     
  ----------------------------- ----- ---------------- ---- ----------------------- ---- ----------------------- ------- ---- ---- -------
  Total                         100   42               58   0.766                   38   62                      0.574   44   56   0.151
    Male                        65    28               37                           26   39                              32   33   
    Female                      35    14               21                           12   23                              12   23   
  Age (years)                                               0.623                                                0.84              0.824
    ≥60                         33    15               18                           13   20                              14   19   
    \<60                        67    27               40                           25   42                              30   37   
  KPS score                                                 0.101                                                0.096             0.642
    ≥80                         75    35               40                           32   43                              34   41   
    \<80                        25    7                18                           6    19                              10   15   
  Differentiation                                           0.06                                                 0.324             0.967
    Well                        18    4                14                           5    13                              8    10   
    Poor                        82    38               44                           33   49                              36   46   
  Number of metastatic organs                               0.463                                                0.552             0.422
    \>2                         41    19               22                           17   24                              20   21   
    ≤2                          59    23               36                           21   38                              24   35   
  Liver metastasis                                          0.654                                                0.709             0.627
    Present                     45    20               25                           18   27                              21   24   
    Absent                      55    22               33                           20   35                              23   32   
  Peritoneal metastasis                                     0.609                                                0.638             0.594
    Present                     47    21               26                           19   28                              22   25   
    Absent                      53    21               32                           19   34                              22   31   

PD-1, programmed cell death protein 1; CD, cluster of differentiation; KPS, Karnofsky performance score.

###### 

Univariate analysis of clinicopathological factors for overall survival in gastric cancer.

  Parameters                                   Hazard ratio   95% confidence interval   P-value
  -------------------------------------------- -------------- ------------------------- ---------
  Age (≥60 vs. \<60 years)                     1.885          1.024--3.895              0.067
  Sex (male vs. female)                        1.603          0.876--4.563              0.168
  KPS score (≥8 vs. \<80)                      2.059          1.556--6.345              0.043
  Differentiation (well vs. poor)              2.167          1.543--4.324              0.031
  Number of metastatic organs (\<2 vs. ≤2)     3.041          2.123--7.342              0.032
  Liver metastasis (present vs. absent)        3.234          2.246--9.213              0.047
  Peritoneal metastasis (present vs. absent)   2.567          1.526--5.563              0.038
  PD-1^+^/CD3^+^ (high vs. low)                2.066          1.311--3.257              0.005
  PD-1^+^/CD3^+^CD4^+^ (high vs. low)          1.857          1.171--2.946              0.028
  PD-1^+^/CD3^+^CD8^+^ (high vs. low)          1.796          1.159--2.784              0.023

PD-1, programmed cell death protein 1; CD, cluster of differentiation; KPS, Karnofsky performance score.

###### 

Multivariate analysis of clinicopathological factors for disease special survival in gastric cancer.

  Parameters                                   Hazard ratio   95% confidence interval   P-value
  -------------------------------------------- -------------- ------------------------- ---------
  KPS score (≥8 vs. \<80)                      1.767          1.543--6.324              0.131
  Differentiation (well vs. poor)              1.159          0.756--4.345              0.243
  Number of metastatic organs (\>2 vs. ≤2)     2.041          1.123--7.342              0.126
  Liver metastasis (present vs. absent)        2.289          2.239--11.213             0.147
  Peritoneal metastasis (present vs. absent)   2.136          1.238--8.175              0.264
  PD-1^+^/CD3^+^ (high vs. low)                2.145          1.325--5.232              0.015
  PD-1^+^/CD3^+^CD4^+^ (high vs. low)          1.866          1.273--3.243              0.034
  PD-1^+^/CD3^+^CD8^+^ (high vs. low)          1.817          1.099--3.675              0.033

PD-1, programmed cell death protein 1; CD, cluster of differentiation; KPS, Karnofsky performance score.
